Professor Tina Vilsbøll
Professor Tina Vilsbøll
Director, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark
Verified email at
Cited by
Cited by
Liraglutide and cardiovascular outcomes in type 2 diabetes
SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ...
New England Journal of Medicine 375 (4), 311-322, 2016
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ...
N Engl J Med 375, 1834-1844, 2016
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst
Diabetes 50 (3), 609-613, 2001
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, 2012
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, AG Juul, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 88 (6), 2706-2713, 2003
Incretins, insulin secretion and type 2 diabetes mellitus
T Vilsbøll, JJ Holst
Diabetologia 47 (3), 357-366, 2004
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsbøll, T Krarup, S Madsbad, J Holst
Diabetologia 45 (8), 1111-1119, 2002
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of …
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courrèges, ...
Diabetes care 30 (6), 1608-1610, 2007
The incretin system and its role in type 2 diabetes mellitus
JJ Holst, T Vilsbøll, CF Deacon
Molecular and cellular endocrinology 297 (1-2), 127-136, 2009
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ...
New England Journal of Medicine 381 (9), 841-851, 2019
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsbøll, H Agersø, T Krarup, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 2003
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
T Vilsbøll, T Krarup, S Madsbad, JJ Holst
Regulatory peptides 114 (2-3), 115-121, 2003
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ...
Diabetes 56 (8), 1951-1959, 2007
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T Vilsbøll, J Rosenstock, H Yki‐Järvinen, WT Cefalu, Y Chen, E Luo, ...
Diabetes, Obesity and Metabolism 12 (2), 167-177, 2010
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with …
PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ...
Diabetologia 52 (2), 199-207, 2009
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen, P Alexandersen, NH Bjarnason, T Vilsbøll, B Hartmann, ...
Journal of Bone and Mineral Research 18 (12), 2180-2189, 2003
Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 …
T Vilsbøll, B Brock, H Perrild, K Levin, HH Lervang, K Kølendorf, T Krarup, ...
Diabetic Medicine 25 (2), 152-156, 2008
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
KJ Hare, T Vilsbøll, M Asmar, CF Deacon, FK Knop, JJ Holst
Diabetes 59 (7), 1765-1770, 2010
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of …
T Vilsbøll, FK Knop, T Krarup, A Johansen, S Madsbad, S Larsen, ...
The Journal of Clinical Endocrinology & Metabolism 88 (10), 4897-4903, 2003
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop
Diabetes 60 (12), 3103-3109, 2011
The system can't perform the operation now. Try again later.
Articles 1–20